Nothing Special   »   [go: up one dir, main page]

NO20026156L - Kinolinyl og benzotiazolyl ppar-gamma modulatorer - Google Patents

Kinolinyl og benzotiazolyl ppar-gamma modulatorer

Info

Publication number
NO20026156L
NO20026156L NO20026156A NO20026156A NO20026156L NO 20026156 L NO20026156 L NO 20026156L NO 20026156 A NO20026156 A NO 20026156A NO 20026156 A NO20026156 A NO 20026156A NO 20026156 L NO20026156 L NO 20026156L
Authority
NO
Norway
Prior art keywords
benzothiazolyl
quinolinyl
ppar
substituted
unsubstituted
Prior art date
Application number
NO20026156A
Other languages
English (en)
Other versions
NO20026156D0 (no
NO325448B1 (no
Inventor
Lawrence Ray Mcgee
Jonathan B Houze
Steven M Rubenstein
Atsushi Hagiwara
Noboru Furukawa
Hisashi Shinkai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO20026156D0 publication Critical patent/NO20026156D0/no
Publication of NO20026156L publication Critical patent/NO20026156L/no
Publication of NO325448B1 publication Critical patent/NO325448B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Quinoline Compounds (AREA)
  • Holo Graphy (AREA)
NO20026156A 2000-06-28 2002-12-20 Kinolinyl og benzotiazolyl ppar-gamma modulatorer, sammensetning omfattende forbindelsen og anvendelse derav NO325448B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21481000P 2000-06-28 2000-06-28
PCT/US2001/020756 WO2002000633A1 (en) 2000-06-28 2001-06-27 Quinolinyl and benzothiazolyl ppar-gamma modulators

Publications (3)

Publication Number Publication Date
NO20026156D0 NO20026156D0 (no) 2002-12-20
NO20026156L true NO20026156L (no) 2003-02-25
NO325448B1 NO325448B1 (no) 2008-05-05

Family

ID=22800496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026156A NO325448B1 (no) 2000-06-28 2002-12-20 Kinolinyl og benzotiazolyl ppar-gamma modulatorer, sammensetning omfattende forbindelsen og anvendelse derav

Country Status (25)

Country Link
EP (1) EP1296967B1 (no)
JP (1) JP4515026B2 (no)
KR (1) KR100771286B1 (no)
CN (1) CN1243741C (no)
AT (1) ATE327984T1 (no)
AU (2) AU7163701A (no)
BR (1) BRPI0112115B8 (no)
CA (1) CA2412723C (no)
CY (1) CY1105126T1 (no)
CZ (1) CZ302982B6 (no)
DE (1) DE60120163T2 (no)
DK (1) DK1296967T3 (no)
EA (1) EA005976B1 (no)
ES (1) ES2265435T3 (no)
HK (1) HK1052351B (no)
HU (1) HUP0301482A3 (no)
IL (2) IL153461A0 (no)
MX (1) MXPA02012708A (no)
NO (1) NO325448B1 (no)
NZ (1) NZ523229A (no)
PL (1) PL214670B1 (no)
PT (1) PT1296967E (no)
SK (1) SK288236B6 (no)
WO (1) WO2002000633A1 (no)
ZA (1) ZA200210283B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
WO2001082916A2 (en) 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
IL160845A0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
US6716842B2 (en) 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US7238717B2 (en) 2002-05-24 2007-07-03 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
DK1562940T3 (da) 2002-11-18 2007-10-01 Chemocentryx Inc Arylsulfonamider
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
NZ542072A (en) 2003-02-13 2007-11-30 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
JP2007525449A (ja) * 2003-04-11 2007-09-06 ザ ユニバーシティー オブ テネシー リサーチ ファウンデーション リゾホスファチジン酸アナログおよび新生内膜形成の阻害方法
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
WO2004106276A1 (ja) * 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
ES2343640T3 (es) * 2004-08-12 2010-08-05 Amgen Inc. Bisaril-sulfonamidas.
CA2637375A1 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
NZ569728A (en) 2006-01-25 2010-11-26 Wellstat Therapeutics Corp Compounds for the treatment of metabolic disorders
US20090176885A1 (en) 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN101421255A (zh) * 2006-02-15 2009-04-29 艾博特公司 新的乙酰辅助a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合症中的应用
TW200817364A (en) * 2006-09-21 2008-04-16 Nicholas Piramal India Ltd Compounds for the treatment of metabolic disorders
WO2012162463A1 (en) * 2011-05-25 2012-11-29 Janssen Pharmaceutica Nv Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation
EP3267994A4 (en) 2015-03-09 2018-10-31 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのPPARγアゴニスト
CN109651208B (zh) * 2017-10-10 2022-01-04 中国科学院上海药物研究所 N-芳基磺酰胺类化合物,其药物组合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3632329A1 (de) * 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
ES2317688T3 (es) * 1998-01-29 2009-04-16 Amgen Inc. Moduladores ppar-gamma.
CN1171872C (zh) * 1999-06-30 2004-10-20 图拉列克股份有限公司 调节PPARγ活性的化合物

Also Published As

Publication number Publication date
JP2004501905A (ja) 2004-01-22
AU7163701A (en) 2002-01-08
NZ523229A (en) 2004-10-29
HK1052351A1 (en) 2003-09-11
WO2002000633A1 (en) 2002-01-03
PL359996A1 (en) 2004-09-06
AU2001271637B2 (en) 2006-05-04
EP1296967B1 (en) 2006-05-31
PL214670B1 (pl) 2013-08-30
SK18352002A3 (sk) 2003-04-01
HUP0301482A3 (en) 2005-12-28
CA2412723C (en) 2010-12-14
IL153461A (en) 2007-10-31
BR0112115A (pt) 2003-04-29
DE60120163T2 (de) 2007-04-12
SK288236B6 (sk) 2015-01-07
JP4515026B2 (ja) 2010-07-28
EP1296967A1 (en) 2003-04-02
ES2265435T3 (es) 2007-02-16
IL153461A0 (en) 2003-07-06
EA200300078A1 (ru) 2003-08-28
ZA200210283B (en) 2005-09-28
CN1243741C (zh) 2006-03-01
HK1052351B (zh) 2006-11-03
CZ20024197A3 (cs) 2003-06-18
NO20026156D0 (no) 2002-12-20
MXPA02012708A (es) 2003-09-22
DE60120163D1 (de) 2006-07-06
BRPI0112115B8 (pt) 2021-05-25
DK1296967T3 (da) 2006-10-02
KR20030024713A (ko) 2003-03-26
HUP0301482A2 (hu) 2003-09-29
BRPI0112115B1 (pt) 2016-07-26
CN1438998A (zh) 2003-08-27
KR100771286B1 (ko) 2007-10-29
NO325448B1 (no) 2008-05-05
CY1105126T1 (el) 2010-03-03
ATE327984T1 (de) 2006-06-15
PT1296967E (pt) 2006-10-31
CA2412723A1 (en) 2002-01-03
EA005976B1 (ru) 2005-08-25
CZ302982B6 (cs) 2012-02-01

Similar Documents

Publication Publication Date Title
NO20026156D0 (no) Kinolinyl og benzotiazolyl ppar-gamma modulatorer
PL340451A1 (en) Safe information transfer form revealing any attempts of manipulations by unauthorised persons
FI861995A0 (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(4-benzoyl-1-piperidinyl)-1 -fenylalkanolderivat.
FI921950A0 (fi) Foerfarande foer framstaellning av n-alkylenpiperidinofoereningar och enantiomerer daerav anvaendabara som laekemedel.
TR200201613T2 (tr) Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler
DK0754682T3 (da) Aminostilbazolderivat og lægemiddel
ATE152725T1 (de) Silylierte acetylcholinesterase inhibitoren
AU574449B2 (en) Nitrification-inhibiting 1-hydroxypyrazole
NO20000282L (no) Dispersjon av titanpartikler omfattende et bindemiddel basert põ et polyorganosiloksan
NO991686L (no) Anvendelse av sarkosinater som asfaltendispergatorer
AU569326B2 (en) 2-(n-pyrrolidino)-3-isobutoxy-n-substituted phenyl-n-benzyl-propylamines
PT652867E (pt) Derivados novos de piridil-e pirimidilpiperazina
HUP0400474A2 (hu) Klórozott pirimidinek előállítása
DE69706355D1 (de) Alkylendiamin-Derivate als Arzneimittel zur Behandlung von Geschwüren und Hemmung von Helicobacter pylori
FI915025A0 (fi) 8-azabicyklo(3,2,1) oktylalkyltiazolidinoner, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
DK166981A (da) 4-hydroxy-1,2-benzisothiazol-3(2h)-on-1,1-dioxider og salte deraf fremgangsmaade til deres fremstilling samt deres anvendelse
FR349345A (fr) Dispositif de sécurité contre l'effraction des portes
IE812605L (en) 2-(n-aryl-n-1,2,3-thiadiazolylcarbonyl)-aminobutyrolactones

Legal Events

Date Code Title Description
MK1K Patent expired